Current and future therapies for the treatment of histamine-induced angioedema

References

• Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticarial: 2014 update. J Allergy Clin Immunol. 2014 May;133(5):1270–1277.
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53(3):373–388.
   PubMed Web of Science ®Google Scholar
• Moellman JJ, Bernstein JA, Lindsell C. A consensus parameter for the evaluation and management of angioedema in the emergency department. Acad Emerg Med. 2014 April;21(4):469–484.
   PubMed Web of Science ®Google Scholar
• Lin RY, Cannon AG, Teitel AD. Pattern of hospitalizations for angioedema in New York between 1990 and 2003. Ann Allergy Asthma Immunol. 2005;95:159.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31(6):511–519.
   PubMed Web of Science ®Google Scholar
• Carr TF, Saltoun CA. Chapter 21: urticaria and angioedema. Allergy Asthma Proc May-Jun. 2012;33(Suppl 1):S70–2.
   PubMedGoogle Scholar
• Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy. 2007;62(8):842–856.
   PubMed Web of Science ®Google Scholar
• Nosbaum A, Braire-Bourrel M, Dubost R, et al. Prevention of nonsteroidal inflammatory drug-induced urticaria and/or agnioedema. Ann Allergy Asthma Immunol. 2013;110:263–266.
   PubMed Web of Science ®Google Scholar
• Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015 Mar;45(3):547–565.
   PubMed Web of Science ®Google Scholar
• Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109:1057–1063.
   PubMed Web of Science ®Google Scholar
• Frigas E, Parks MA. Acute urticaria and angioedema: diagnostic and treatment considerations. Am J Clin Dermatol. 2009;10(4):239–250.
   PubMed Web of Science ®Google Scholar
• Baram M, Kommuri A, Subhashini A, et al. ACE inhibitor-induced angioedema. J Allergy Clin Immunol Pract. 2013 Sep-Oct;1(5):442–445.
   PubMed Web of Science ®Google Scholar
• Adam A, Cugno M, Molinaro G, et al. Aminopeptidase P in individuals with a history of angio-edema on ACE inhibitors. Lancet. 2002 Jun 15;359(9323):2088–2089.
   PubMed Web of Science ®Google Scholar
• Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006 Nov;26(4):725–737.
   PubMed Web of Science ®Google Scholar
• Epstein TG. Bernstein JA: current and emerging management options for hereditary angioedema in the US. Drugs. 2008;68(18):2561–2573.
   PubMed Web of Science ®Google Scholar
• Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, et al. Food allergy: a practice parameter update 2014. J Allergy Clin Immunol. 2014Nov;1345:1016–1025.
   PubMed Web of Science ®Google Scholar
• Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105:259–273.
   PubMed Web of Science ®Google Scholar
• Lin RY, Schwartz LB, Corry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol. 2000;106:65e71 (III).
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Moellman JJ. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. International Journal of Emergency Medicine. 2012;5:39.
   PubMedGoogle Scholar
• Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010Sep;1263:477–480.
   PubMed Web of Science ®Google Scholar
• Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. Ann Allergy Asthma Immunol. 2014;113:599–608.
   PubMed Web of Science ®Google Scholar
• Lin RY, Curry A, Pesola GR, et al. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Annals of Emergency Medicine. 2000;36(5):462–468.
   PubMed Web of Science ®Google Scholar
• Fine LM, Bernstein JA. Urticaria Guidelines: consensus and Controversies in the European and American Guidelines. Curr Allergy Asthma Rep. 2015 Jun;15(6):30.
   PubMed Web of Science ®Google Scholar
• Powell RJ, DuToit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631–650.
   PubMed Web of Science ®Google Scholar
• Sanchez-Borges M, Asero R, Ansotegu IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. WAO Journal. 2012;5:125–147.
   Google Scholar
• Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86:1014–1018.
   PubMed Web of Science ®Google Scholar
• Breneman D. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother. 1996; 30: 1075-1079. CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria-a double-blind randomised cross-over study. Ann Acad Med Singapore. 1991;20(3):328–330.
   PubMedGoogle Scholar
• Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria-a double-blind randomised cross-over study. Ann Acad Med Singapore. 1991;20(3):328–330.
   PubMedGoogle Scholar
• Finn AF Jr, Kaplan AP, Fretweel R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunology. 1999;104(4):1071–1078.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is a safe and effective treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517–522.
   PubMed Web of Science ®Google Scholar
• Kapp A, Wedi B. Chronic urticaria: clinical aspects, and focus on a new antihistamine, levocetirizine. J Drugs Dermatol. 2004;3:632–639.
   PubMedGoogle Scholar
• Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratidine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung. 1992;42(9):1119–1121.
   PubMed Web of Science ®Google Scholar
• Monroe EW. Relative efficacy and safety of loratidine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992;14(1):17–21.
   PubMed Web of Science ®Google Scholar
• Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat. 2004;15:55–57.
   PubMedGoogle Scholar
• Zuberbier T, Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193:324–327.
   PubMed Web of Science ®Google Scholar
• Kontou-Fili K, Maniakatou G, Demaka P, et al. Therapeutic effect of cetirizine 2HCl in delayed pressure urticaria. Health Sci Rev. 1989;3:23–25.
   Google Scholar
• Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol. 2007;32:34–38.
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine ande desloratidine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010 Mar;125(3):676–682.
   PubMed Web of Science ®Google Scholar
• Simons FE, Sussman GI, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonist hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol. 1995;95(3):685–693.
   PubMed Web of Science ®Google Scholar
• Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol. 1998;102:876–877.
   PubMed Web of Science ®Google Scholar
• Spector S, Tan RA. Antileukotrienes in chronic urticaria. J Allergy Clin Immunol. 1998;101:572.
   PubMed Web of Science ®Google Scholar
• Nettis E, Colanardi MC, Paradiso MT, et al. Desloratidine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind placebo-controlled study. Clin Esp Allergy. 2004;34:1401–1407.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Pacor MI, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratidine and montelukast in monotherapy and desloratidine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114:619–625.
   PubMed Web of Science ®Google Scholar
• Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004;113(1):134–140.
   PubMed Web of Science ®Google Scholar
• Pacor MI, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicyclic acid. Clin Exp Allergy. 2001;31:1607–1614.
   PubMed Web of Science ®Google Scholar
• Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy. 2002;31(12):1763–1768.
   Web of Science ®Google Scholar
• Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol. 1985;12:669–675.
   PubMed Web of Science ®Google Scholar
• Kamide R, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen for chronic urticaria: multicenter double-blind comparative study with clemastine. Ann Allergy Asthma Immunol. 1989;62(4):322–325.
   Google Scholar
• Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol. 1989;83(4):756–763.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014 Jul;69(7):868–887.
   PubMed Web of Science ®Google Scholar
• Stellato C, De Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin histamines. J Invest Dermatol. 1992;98:800–804.
   PubMed Web of Science ®Google Scholar
• Grattan CH, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic idiopathic urticaria. Br J Dermatol. 2000;143:365–372.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Colombo D. Cyclosporine in chronic idiopathic urticaria: a double-blind. randomized, placebo-controlled study. J Am Acad Dermatol. 2006;55(4):705–709.
   PubMed Web of Science ®Google Scholar
• Baskan EB, Tunali S, Turker T, et al. Comparison of short- and long-term cyclosporin A therapy in chronic idiopathic urticaria. J Dermatolog Treat. 2004;15(3):164–168.
   PubMedGoogle Scholar
• O’Donnell BF, Barr RM, Kobza Black A, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol. 1998;138:101–106.
   PubMed Web of Science ®Google Scholar
• Grattan CEH, Francis DM, Slater NGP, et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992;339:1078–1080.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316.
   PubMed Web of Science ®Google Scholar
• Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17:1–342.
   PubMed Web of Science ®Google Scholar
• Mauer M, Rosen KE, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–935.
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128:202–209.
   PubMed Web of Science ®Google Scholar
• Van Del Elzen M, Go MFCL, Knulst A, et al. Efficacy of treatment of non-hereditary angioedema. Clinic Rev Allergy Immunol. 2016. DOI:10.1007/s12016-016-8585-0
   Web of Science ®Google Scholar
• Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012 Nov-Dec;33(Suppl 1):S145–56.
   PubMed Web of Science ®Google Scholar